PRMT5 imposed a dual repression on DDIT3 transcription to promote the malignancy of hepatocellular carcinoma

Figure 6 HLCL-61 was a promising strategy of hepatocellular carcinoma therapy. A-F: The growth curve and weight of tumors generated by huh7 or HepG2 cells, which treated with vehicle and HLCL-61 (50mg/kg); G-I: HLCL-61 significantly reduced the volume and weight of tumors in patient-derived xenografts models; J and K: The Ki67 (scale bar = 50 μm) and DDIT3 (scale bar = 100 μm) staining of tumor tissues. Data are presented as the mean ± SD. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001. PDX: Patient-derived xenografts.